Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruption.

IF 3.4 2区医学 Q3 IMMUNOLOGY

AIDS Pub Date : 2025-03-04 DOI:10.1097/QAD.0000000000004171

Graeme Moyle, Joshua Gruber, Megan Dunbar, Janna Radtchenko, Andrew J Frick, Andrea Marongiu, Paul E Sax, Travis Lim, Steven Santiago, Paul Benson, Charles Walworth, Richard A Elion

{"title":"Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruption.","authors":"Graeme Moyle, Joshua Gruber, Megan Dunbar, Janna Radtchenko, Andrew J Frick, Andrea Marongiu, Paul E Sax, Travis Lim, Steven Santiago, Paul Benson, Charles Walworth, Richard A Elion","doi":"10.1097/QAD.0000000000004171","DOIUrl":null,"url":null,"abstract":"Objective: Treatment adherence remains critical in maintaining HIV RNA suppression on antiretroviral therapy. High genetic barrier regimens constructed with three long half-life agents may prevent resistance emergence and can be potentially started or restarted after antiretroviral treatment interruption (TI).Methods: Data from the TRIO US HIV cohort were used to identify adult people with HIV initiating a new ART regimen from January 2021 - November 2023 and describe prevalence of TIs (defined as ≥90 days without dispensed ART). Virologic outcomes were assessed among those restarting or switching to B/F/TAF after TI.Results: Of 2710 people with HIV, 765 (28%) experienced TI. Compared to individuals without TIs, those with TIs had higher proportion of females (24% vs 19%), black race (50% vs 35%), substance use (14% vs 9%), CD4 <200 cells/mm3 (15% vs 8%) and lower proportion with commercial insurance (48% vs 62%) or virologic suppression at initiation (76% vs 85%). Among 379 who restarted or switched to B/F/TAF following TI, 245 (65%) were suppressed at restart; 137 (56%) had ≥1 viral load (VL) after TI, of whom 129 (94%) maintained suppression. Of 87 with unknown viral status at restart, 46 (53%) had ≥1 VL during follow-up, of whom 44 (96%) achieved suppression. Among 47 viremic at restart, 27 (57%) had ≥1 VL after TI. Of them, 70% were suppressed during follow-up. No integrase inhibitor resistance emergence was observed.Conclusion: High levels of suppression following TI may suggest B/F/TAF regimen forgiveness making it an appropriate choice for treatment switch or restart.","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/QAD.0000000000004171","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Treatment adherence remains critical in maintaining HIV RNA suppression on antiretroviral therapy. High genetic barrier regimens constructed with three long half-life agents may prevent resistance emergence and can be potentially started or restarted after antiretroviral treatment interruption (TI).

Methods: Data from the TRIO US HIV cohort were used to identify adult people with HIV initiating a new ART regimen from January 2021 - November 2023 and describe prevalence of TIs (defined as ≥90 days without dispensed ART). Virologic outcomes were assessed among those restarting or switching to B/F/TAF after TI.

Results: Of 2710 people with HIV, 765 (28%) experienced TI. Compared to individuals without TIs, those with TIs had higher proportion of females (24% vs 19%), black race (50% vs 35%), substance use (14% vs 9%), CD4 <200 cells/mm3 (15% vs 8%) and lower proportion with commercial insurance (48% vs 62%) or virologic suppression at initiation (76% vs 85%). Among 379 who restarted or switched to B/F/TAF following TI, 245 (65%) were suppressed at restart; 137 (56%) had ≥1 viral load (VL) after TI, of whom 129 (94%) maintained suppression. Of 87 with unknown viral status at restart, 46 (53%) had ≥1 VL during follow-up, of whom 44 (96%) achieved suppression. Among 47 viremic at restart, 27 (57%) had ≥1 VL after TI. Of them, 70% were suppressed during follow-up. No integrase inhibitor resistance emergence was observed.

Conclusion: High levels of suppression following TI may suggest B/F/TAF regimen forgiveness making it an appropriate choice for treatment switch or restart.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

AIDS 医学-病毒学

CiteScore

5.90

自引率

5.30%

发文量

478

审稿时长

3 months

期刊介绍： Publishing the very latest ground breaking research on HIV and AIDS. Read by all the top clinicians and researchers, AIDS has the highest impact of all AIDS-related journals. With 18 issues per year, AIDS guarantees the authoritative presentation of significant advances. The Editors, themselves noted international experts who know the demands of your work, are committed to making AIDS the most distinguished and innovative journal in the field. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.